Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Galmed Pharma (GLMD) Tops Q3 EPS by 8c
November 6, 2019 7:23 AM ESTGalmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.21), $0.08 better than the analyst estimate of ($0.29).
Financial Summary - Third Quarter 2019 vs. Third Quarter 2018:
Cash and cash equivalents, short-term deposits and marketable securities totaled $79.7 million as of September 30, 2019, compared to $90.2 million at December 31, 2018.Net loss of $4.5 million, or ($0.21) per share, for the three months ended September 30, 2019, compared to a net loss of $1.0 million, or ($0.05) per share, for the three months ended September 30, 2018.Research and... More